Hims & Hers Health introduces compounded GLP-1 injections to its weight loss program.

• Hims & Hers Health is launching compounded GLP-1 weight loss injections for digital pharmacy customers.
• In recent months, the GLP-1 market, which has been dominated by pharmaceutical giant Novo Nordisk, has experienced supply constraints due to the increasing popularity of drugs such as Ozempic and Wegovy.
• Andrew Dudum, CEO of Hims & Hers, stated to CNBC that the company is "assured" that customers will have a steady supply of compounded medications.

The digital pharmacy startup announced on Monday that it is providing access to compounded GLP-1 weight loss injections.

The company, which provides direct-to-consumer treatments for various conditions, introduced a weight loss program in December. However, GLP-1 medications, a popular class of drugs used for weight loss, were not included in the program initially.

Hims & Hers customers can obtain compounded GLP-1 medications through a prescription from a licensed healthcare provider on their platform. The company plans to offer branded GLP-1 medications to customers once a consistent supply is available.

The company's oral medication kits and compounded GLP-1 injections will both start at $79 and $199 a month, respectively.

Hims & Hers anticipates that its weight loss program will generate over $100 million in revenue by the end of 2025, even before adding compounded GLP-1s to its portfolio. The company intends to provide updated revenue guidance in its next earnings report.

The GLP-1 market, currently dominated by a pharmaceutical giant, has been facing supply constraints due to recent expanded approval of the drugs by health regulators and increased health coverage.

Compounded GLP-1s can be prepared by certain manufacturers if they meet FDA requirements, as these medications mimic a hormone produced in the gut to control appetite and blood sugar levels.

The FDA advised against using a compounded GLP-1 drug in January, stating that patients should opt for an approved drug like Wegovy instead.

Andrew Dudum, CEO of Hims & Hers, stated to CNBC that the company is "assured" that customers will have a steady supply of compounded medications.

Hims & Hers has spent the past year studying the GLP-1 supply chain and has partnered with a major generic manufacturer in the country that has FDA supervision.

He stated in an interview that we have a level of exclusivity with that facility that ensures our customers receive consistent volume and supply.